Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages

Lemtrada works great for some and alleviates their RRMS symptoms but carries the ultimate side effect when it does not

Friday, September 6, 2019 - Anti-multiple sclerosis drug Lemtrada carries side effects that are so deadly and serious that patients must be fully advised of them before taking the medication. Patients that suffer from relapse-remitting multiple sclerosis (RRMS) may choose Lemtrada infusion only after all other forms of treatment from their disease have failed. Lemtrada is a drug of last resort. Lemtrada patients report developing several unique life-threatening conditions immediately following and sometimes during their Lemtrada infusion. According to Multiple Sclerosis News Today, Lemtrada is administered "12 mg dosages per day, given in four-hour intravenous (into the vein) infusions over five consecutive days, followed by infusions on three consecutive days one year later. Lemtrada works by inactivating inflammatory immune B and T cells, which can help slow down the progression of MS." Lemtrada Multiple Sclerosis lawyers representing families and individuals in the United States harmed by pharmaceutical drugs and offer a free consultation before filing a claim.

Deciding to take Lemtrada is like choosing between the lesser of two evils. Lemtrada patients must decide what is worse, having to suffer from ever more frequent and severe MS relapses or risking their life entirely by taking the drug, not an envious position to be put in. On the one hand, some Lemtrada patients have been thrilled with the results they have achieved in managing the relapses they were experiencing from multiple sclerosis. Some patients report that the number of relapses of multiple sclerosis that they experience has decreased by up to 70%. Lemtrada is officially classified as a disease-modifying drug (DMD). As such, the drug reduces the number of relapses an MS patient experiences by one half on average. Patients also attribute recognizing smaller and fewer new occurrences of brain lesions, a condition thought to trigger MS relapses. Lemtrada also lessens the severity of and speeds the recovery from MS symptoms when they do occur. Other patients are not sol lucky and are forced to cope with being permanently paralyzed by a Lemtrada stroke or have suffered the ultimate side effect, instant unexpected death.

In addition to stroke and heart attack, Sanofi, maker of Lemtrada, warns prospective patients that the drug causes serious autoimmune problems that cause one's immune cells to aggressively attack other cells and organs in the body "which can be serious and cause death." Other complications caused by Lemtrada are "Immune thrombocytopenia, which is when reduced platelet counts in your blood cause severe bleeding that, if not treated, may cause life-threatening problems, and kidney problems called anti-glomerular basement membrane disease, which can, if untreated, lead to severe kidney damage, kidney failure that needs dialysis, a kidney transplant, or death, " according to the Sanofi Genzyme website.

Sanofi warns of serious infusion reactions that may occur while a patient is receiving their Lemtrada infusion or up to 24 hours later including the possibility of sudden death. Patients experience an immediate allergic reaction and or have trouble breathing or heart rhythm issues. Health care providers administering Lemtrada are required to watch for and be able to immediately treat these conditions and will stop the Lemtrada infusion. Signs to watch for that indicate something may be wrong include "swelling in your mouth or throat, fast, slow, or irregular heartbeat, trouble breathing, chest pain, weakness, and rash.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.